Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Neonatal hypoglycaemia

Paediatrics and child health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Neurological signs or glucose below 1.0 mmol/L

Seizures, reduced consciousness, apnoea, marked hypotonia or any blood glucose below 1.0 mmol/L requires urgent intravenous glucose and neonatal review, while other causes of illness are assessed.

Action: Stabilise airway, breathing, circulation and temperature; obtain an accurate glucose and critical blood samples if this does not delay treatment. Establish IV access, give 10% glucose 2.5 mL/kg over 5 minutes and start 10% glucose at 60 mL/kg/day under the BAPM term-infant pathway, then recheck glucose after 30 minutes and titrate through a neonatal protocol. Use buccal 40% dextrose gel as a bridge while obtaining access, not as definitive treatment for neurological signs.

Synopsis

Identify newborns at risk, support feeding and metabolic adaptation, interpret glucose within the BAPM operational-threshold framework, and treat symptomatic, severe or persistent hypoglycaemia without delaying investigation.

  • Screen only babies with recognised risk or abnormal signs; routine testing of healthy term babies without risk can disrupt feeding and cause unnecessary treatment.
  • Risk includes maternal diabetes, beta-blocker exposure, fetal growth restriction, birth weight below the 2nd centile, macrosomia, hypothermia and significant perinatal illness.
  • Feed an at-risk well baby within the first hour, support skin-to-skin contact and check blood glucose before the second feed at 2–4 hours of age.
  • Use a ward glucose analyser or blood-gas analyser at low ranges. Bedside meters may screen, but confirm unexpectedly low or persistent values without delaying treatment.
  • BAPM operational thresholds for term infants in the first 72 hours are below 1.0 mmol/L at any time, below 2.5 mmol/L with abnormal signs, or persistent below 2.0 mmol/L on repeat in an at-risk well baby.
  • First-line for a well, feeding term infant with glucose 1.0–1.9 mmol/L is feeding support plus 40% dextrose gel 200 mg/kg, equivalent to 0.5 mL/kg, massaged into the buccal mucosa.
  • Recheck glucose about 30 minutes after gel and feeding. Repeat and escalate according to the BAPM/local pathway; repeated gel must not postpone neonatal assessment.
  • For neurological signs or glucose below 1.0 mmol/L, give urgent IV 10% glucose and start a controlled infusion; obtain a critical sample first only if immediately available.
  • Do not use undiluted concentrated glucose through peripheral veins. Calculate the glucose infusion rate, prescribe pump rate clearly and use independent neonatal dose checks.
  • Investigate sepsis, hypothermia, hypoxia and feeding failure concurrently. A corrected glucose does not explain why it fell.
  • Take a critical sample during recurrent severe hypoglycaemia for laboratory glucose, insulin, C-peptide, ketones, free fatty acids, cortisol, growth hormone and metabolic tests guided by specialists.
  • Before discharge confirm stable pre-feed glucose through several feed-fast cycles, an effective feeding plan, resolved cause or specialist plan and clear parental safety-netting.

    • Key red flags

    Seizures, altered consciousness, apnoea, cyanosis, marked hypotonia or abnormal feeding with low glucose requires emergency IV treatment and investigation.

    A glucose below 1.0 mmol/L at any time is a BAPM operational threshold for urgent intervention, even when signs appear subtle.

    A glucose below 2.5 mmol/L with abnormal clinical signs requires urgent treatment; symptoms are nonspecific and sepsis must remain in the differential.

    Two or more values below 2.0 mmol/L in an at-risk but asymptomatic term infant indicate persistent hypoglycaemia and need neonatal assessment.

    Recurrent or treatment-resistant hypoglycaemia, especially with glucose requirement above 8 mg/kg/min, raises hyperinsulinism or metabolic and endocrine disease.

    Hypoglycaemia beyond the expected transition, hepatomegaly, acidosis, abnormal ketones, ambiguous genitalia or family history requires a diagnostic critical sample and specialist input.

    Investigation priorities

    01
    First-line: accurate blood glucose measurementFirst stepFirst line

    Confirm hypoglycaemia and guide time-critical treatment.

    Management branches

    RiskPrevent and screen

    A term baby is well but has a recognised hypoglycaemia risk.

    1. Keep warm and in skin-to-skin contact and feed within 1 hour.
    2. Measure glucose before the second feed at 2–4 hours and assess feeding directly.
    3. Continue pre-feed monitoring and feeding support until the BAPM discharge criteria are met.

    Key medicines

    Dextrose 40% oral gel200 mg/kg, equivalent to 0.5 mL/kg, massaged into the buccal mucosa and followed immediately by an effective feed. Repeat only within the current BAPM and local pathway after reassessment.Not definitive treatment for neurological signs, severe illness or glucose below 1.0 mmol/L. Check concentration and dose by current weight, avoid simply squirting it into the throat, document cumulative doses and do not let repeated gel delay IV treatment.
    Glucose 10% intravenousUnder the BAPM term pathway for glucose below 1.0 mmol/L or abnormal signs, give 2.5 mL/kg IV over 5 minutes, then start 60 mL/kg/day by infusion and recheck glucose after 30 minutes. Titrate glucose infusion rate through the neonatal protocol.Use neonatal pump and independent dose checks. Obtain critical samples first only if treatment is not delayed. Monitor line site, fluids, sodium and glucose closely; higher concentrations usually require central access and specialist prescribing.
    Open full textbook →Answer 2 questions
    Sources and review status3 sources · checked 27 Aug 2026 · clinical review pending+
    Sources

    Sources and review status

    National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

    • BAPM identification and management of neonatal hypoglycaemiaCurrent UK term-infant operational thresholds, feeding, gel, IV treatment and discharge pathway.
    • NICE NG194 postnatal care recommendationsNewborn feeding, examination and hypoglycaemia risk assessment in postnatal care.
    • NICE NG3 diabetes in pregnancyPostnatal testing and feeding of babies born to women with diabetes.

    Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

    Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom